-transparent.png){kind=logo}
The authors present a review of literature on the initial rationale and efficacy in clinical trials of carbamazepine (CBZ) in the treatment of alcohol withdrawal, and the pharmacokinetics of carbamazepine in alcoholics as well. Neurophysiological and clinical studies support the kindling hypothesis in the pathophysiology of alcohol withdrawal. The exact physiological action mechanism of CBZ has not been entirely examined. However, the "antikindling effects" are of particular importance in epilepsy and other neurological and psychiatric conditions. Numerous controlled studies were able to demonstrate the effectiveness of carbamazepine in the treatment of alcohol withdrawal symptoms and have compared its properties to other drugs such as clomethiazole and benzodiazepines. Carbamazepine could be a useful alternative to conventional therapeutic approaches, especially in the treatment of mild and moderate alcohol withdrawal symptoms, and alcohol withdrawal with generalized tonic-clonic seizures.
T Wolańczyk, and
M Wojnar, and
A Cedro
October 1990,
International clinical psychopharmacology,
T Wolańczyk, and
M Wojnar, and
A Cedro
January 1991,
The British journal of psychiatry : the journal of mental science,
T Wolańczyk, and
M Wojnar, and
A Cedro
September 2005,
Addiction biology,
T Wolańczyk, and
M Wojnar, and
A Cedro
January 1986,
Alcohol (Fayetteville, N.Y.),
T Wolańczyk, and
M Wojnar, and
A Cedro
December 1992,
Alcoholism, clinical and experimental research,
T Wolańczyk, and
M Wojnar, and
A Cedro
September 2002,
The Journal of family practice,
T Wolańczyk, and
M Wojnar, and
A Cedro
June 1979,
The British journal of addiction to alcohol and other drugs,
T Wolańczyk, and
M Wojnar, and
A Cedro
October 1979,
Neurology,
T Wolańczyk, and
M Wojnar, and
A Cedro
March 1990,
The American journal of psychiatry,
T Wolańczyk, and
M Wojnar, and
A Cedro
January 1987,
Psychiatria polska,
